Tuberculosis laboratory findings: Difference between revisions

Jump to navigation Jump to search
 
(4 intermediate revisions by the same user not shown)
Line 41: Line 41:
|}
|}


A sample of [[pleural]] [[exudate]] can be analyzed by [[cytopathology]] or at a cell count lab.  Samples are usually [[lymphocyte]] predominant, and cytopathology is more accurate than cell count labs at detecting lymph.  If there is more fluid present, then an AFB lab is more appropriate.  A pleural exudate lab test may find sterile [[pyuria]] (especially in [[HIV]] positive patients), but overall this finding is fairly uncommon.
A sample of [[pleural]] [[exudate]] should be analyzed by [[cytopathology]] or at a cell count lab.  Samples are often [[lymphocyte]] predominant, and cytopathology is more accurate than cell count labs at detecting lymph.  If there is more [[fluid]] present, then an [[Acid-fast|AFB]] lab is more appropriate.  Sometimes, a [[pleural]] [[exudate]] lab test find [[Sterile pyuria differential diagnosis|sterile]] [[pyuria]] (particularly in [[HIV]] positive patients), but overall this finding is fairly uncommon.
Most extra-pulmonary TB is paucibacillary, so the yield of tests is very low. A negative result does not exclude a tuberculosis infection.
Most [[extra-pulmonary TB]] is [[paucibacillary]], hence the yield of tests is very low, and a negative [[test]] result does not exclude [[tuberculosis]] [[infection]].


===Drug Resistance===
===Drug Resistance===
For all patients, the initial ''[[M. tuberculosis]]'' isolate should be tested for [[drug resistance]]. It is important to identify drug resistance as early as possible to ensure effective treatment. Drug susceptibility testing should be repeated for patients who do not respond adequately to treatment or who have positive culture results despite 3 months of therapy. Susceptibility results from laboratories should be reported to the primary health care provider and the state or local TB control programs.
For all patients, the initial ''[[M. tuberculosis]]'' isolate should be tested for [[drug resistance]]. It is necessary to identify drug resistance as early as possible to ensure effective treatment. Drug susceptibility testing has to be repeated for patients who do not respond adequately to treatment or who have positive culture results despite 3 months of therapy. Susceptibility results from laboratories have to be reported to the primary [[health care provider]] and the state or local [[Tuberculosis|TB]] control programs.


===Fluid Analysis===
===Fluid Analysis===


*Peritoneal Fluid:  Leucocyte count: 150-4000 mm³, lymphocytic pleocytosis, protein > 3.0 g/dL, increased LDH.
*[[Peritoneal Fluid]][[Leukocyte]] count: 150-4000 mm³, [[Lymphocyte|lymphocytic]] [[pleocytosis]], [[protein]] > 3.0 g/dL, and increased [[Lactate dehydrogenase|LDH]].
*Cerebrospinal Fluid: High protein, low glucose, increased number of lymphocytes, increased LDH
*[[Cerebrospinal Fluid|Cerebrospinal fluid]]: High [[protein]], low glucose, high number of [[Lymphocyte|lymphocytes]], and elevated [[Lactate dehydrogenase|LDH]] level


===Urinalysis===
===Urinalysis===


*For renal tuberculosis, the classic laboratory finding is sterile pyuria with microscopic hematuria.
*Regarding [[Kidney|renal]] [[tuberculosis]], the classic laboratory finding is [[Sterile pyuria differential diagnosis|sterile pyuria]] with [[microscopic hematuria]].


===Interferon-Gamma Release Assays (IGRAs)===
===Interferon-Gamma Release Assays (IGRAs)===
Interferon-Gamma Release Assays (IGRAs) are whole-blood tests that help in diagnosing [[Mycobacterium tuberculosis]] infection, but they do not differentiate latent tuberculosis infection (LTBI) from tuberculosis disease. Two IGRAs tests that are approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S are The QuantiFERON®-TB Gold In-Tube test (QFT-GIT) and the T-SPOT®.TB test (T-Spot).
[[Interferon-Gamma Release Assays]] ([[Interferon-γ release assays|IGRAs]]) are whole-[[blood]] tests that aids in diagnosing [[Mycobacterium tuberculosis]] infection, but they do not differentiate latent tuberculosis infection (LTBI) from tuberculosis disease. Two IGRAs tests that are approved by the U.S. [[Food and Drug Administration]] ([[FDA]]) and commercially available in the U.S include the [[QuantiFERON-TB Gold|QuantiFERON]]®-TB Gold In-Tube test (QFT-GIT) and the T-SPOT®.TB test ([[T-Spot]]).


IGRAs measure a person’s immune reactivity to M. tuberculosis antigen. White blood cells from most persons that have been infected with M. tuberculosis will release interferon-gamma (IFN-g) when mixed with [[antigens]] (substances that can produce an immune response) derived from M. tuberculosis.
[[Interferon-γ release assays|IGRAs]] measure a person’s [[immune reactivity]] to [[Mycobacterium tuberculosis|M. tuberculosis]] [[Antigenic|antigen]]. [[White blood cells]] from most individuals that have been [[infected]] with [[Mycobacterium tuberculosis|M. tuberculosis]] will produce [[interferon-gamma]] (IFN-g) when mixed with [[antigens]] (substances that can produce an [[immune]] response) derived from M. tuberculosis.


To perform this test, fresh blood samples are mixed with antigens and controls.  The antigens, testing methods, and interpretation criteria for IGRAs differ.
To do this [[test]], fresh [[blood samples]] should be mixed with [[Antigen|antigens]] and controls.  The [[Antigen|antigens]], testing methods, and interpretation [[criteria]] for [[Interferon-γ release assays|IGRAs]] are different.


{| style="border: 0px; font-size: 90%; margin: 3px; width:700px" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px; width:700px" align="center"
Line 70: Line 70:
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Initial Process
| style="padding: 5px 5px; background: #DCDCDC;" |Initial Process
| style="padding: 5px 5px; background: #F5F5F5;" |Process whole blood within 16 hours
| style="padding: 5px 5px; background: #F5F5F5;" |Process whole blood in 16 hours
| style="padding: 5px 5px; background: #F5F5F5;" |Process peripheral blood mononuclear cells (PBMCs) within 8 hours, or if T-Cell Xtend® is used, within 30 hours
| style="padding: 5px 5px; background: #F5F5F5;" |Process peripheral blood mononuclear cells (PBMCs) within 8 hours, or if T-Cell Xtend® is used, within 30 hours
|-
|-
Line 78: Line 78:
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Measurement
| style="padding: 5px 5px; background: #DCDCDC;" |Measurement
| style="padding: 5px 5px; background: #F5F5F5;" |IFN-g concentration
| style="padding: 5px 5px; background: #F5F5F5;" |Interferon-γ concentration
| style="padding: 5px 5px; background: #F5F5F5;" |Number of IFN-g producing cells (spots)
| style="padding: 5px 5px; background: #F5F5F5;" |Number of IFN-g producing cells (spots)
|-
|-
Line 95: Line 95:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*It requires a single patient visit to conduct the test.
*It requires a single patient visit to perform the test.
*The results can be available within 24 hours.
*The results can be available within 24 hours.
*It does not boost responses measured by subsequent tests.
*There are no boosted responses that are measured by subsequent tests.
*A history of prior BCG (bacille Calmette-Guérin) vaccination does not cause a false-positive IGRA test result.
*A history of previous BCG (bacillus Calmette-Guérin) vaccination does not yield a false-positive IGRA test result.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*The blood samples must be processed within 8-30 hours after collection while white blood cells are still viable.
*The blood samples should be processed within 8-30 hours after collection while white blood cells are still viable.
*Errors in collecting or transporting blood specimens or in running and interpreting the assay can decrease the accuracy of IGRAs.
*Errors in collecting or transporting blood specimens or in performing and interpreting the assay may reduce the accuracy of IGRAs.
*There is limited data on the use of IGRAs to predict who will progress to TB disease in the future.
*There is limited data on the use of IGRAs to predict who will progress to TB disease in the future.
*There is limited data on the use of IGRAs for:
*There is also limited data on the use of IGRAs for:


:*Children younger than 5 years of age
:*Children younger than 5 years of age
Line 117: Line 117:
====CDC Recommendations on When to Use IGRA Tests  <small><small><SMALL> Adapted from CDC Interferon-Gamma Release Assays<ref name="CDC TST">{{cite web|url= http://www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm|title= CDC Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection }}</ref></SMALL></small></small>====
====CDC Recommendations on When to Use IGRA Tests  <small><small><SMALL> Adapted from CDC Interferon-Gamma Release Assays<ref name="CDC TST">{{cite web|url= http://www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm|title= CDC Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection }}</ref></SMALL></small></small>====


*IGRAs can also be used in place of (but not in addition to) TST in all situations in which CDC recommends TST as an aid in diagnosing M. tuberculosis infection, with preferences and special considerations noted below.
*[[Interferon-γ release assays|IGRAs]] can also be used in stead of (but not in addition to) [[Mantoux test|TST]] in all conditions in which [[Centers for Disease Control and Prevention|CDC]] recommends TST as an aid in diagnosing [[Mycobacterium tuberculosis|M. tuberculosis]] infection, with preferences and particular considerations noted below.
*This includes contact investigations, testing during pregnancy, and screening of health care workers, and others undergoing serial evaluation for M. tuberculosis infection.
*Contact [[investigations]], testing during [[pregnancy]], in addition to [[screening]] of [[health care workers]], and others undergoing serial evaluation for [[Mycobacterium tuberculosis|M. tuberculosis]] infection.
*Despite the indication of a preference, the use of the alternative test (FDA-approved IGRA or TST) is acceptable medical and public health practice.
*In spite of the indication of a preference, the use of the alternative test ([[FDA]]-approved [[Interferon-γ release assays|IGRA]] or [[Mantoux test|TST]]) are approved medical and [[public health]] practice.
*We should be cautious in interpretation when testing certain populations because of limited data on the use of IGRAs
*We should be alert in interpretation when testing particular populations due to limited data on the use of [[Interferon-γ release assays|IGRAs]]


*Populations in which IGRAs are preferred for testing:
*Populations in which [[Interferon-γ release assays|IGRAs]] are preferred for testing:


:*Persons who have received BCG (either as a vaccine or for cancer therapy)
:*Individuals who received [[BCG]] (either as a [[vaccine]] or for [[Cancer (medicine)|cancer]] therapy)
:*Persons from groups that historically have less chances of return for TST reading.
:*Individuals from groups that historically have less chances of coming back for [[Mantoux test|TST]] reading.


*TST is preferred over IGRAs for children less than 5 years of age.
*[[Mantoux test|TST]] is better than [[Interferon-γ release assays|IGRAs]] for children less than 5 years of age.
*As with TST, IGRAs generally should not be used for testing persons who have a low risk of infection and a low risk of disease due to M. tuberculosis.
*As with [[Mantoux test|TST]], [[Interferon-γ release assays|IGRAs]] generally should not be used for testing individuals who have a low risk of [[infection]] and a low risk of [[tuberculosis]] disease.
*Each institution and TB control program should evaluate the availability and benefits of IGRAs in prioritizing their use.


Routine testing with both TST and IGRA is not recommended. However, results from both tests might be useful in the following situations:
Routine testing with [[Mantoux test|TST]] and [[Interferon-γ release assays|IGRA]] is not recommended, but results from both tests may be useful in the following conditions:


{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px" align="center"
Line 138: Line 137:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*The risk for infection, the risk for progression to disease, and the risk for a poor outcome are high (e.g., HIV-infected persons or children under 5 years of age who are exposed to a person with infectious TB).
*The risk for infection, the risk for progression to active disease, and the risk for a bad outcome are high (e.g., HIV-infected individuals or children under 5 years of age who are exposed to an individual with infectious TB).
*There is clinical suspicion for TB disease (e.g., signs, symptoms, and/or radiographic evidence suggestive of TB disease) and confirmation of M. tuberculosis infection is desired.
*Presence of clinical suspicion for TB disease (e.g., signs, symptoms, and/or radiographic evidence suggestive of TB disease) and confirmation of M. tuberculosis infection is needed.
*Taking a positive result from a second test as evidence of infection increases detection sensitivity.
*Getting a positive result from a second test as evidence of infection increases detection sensitivity of the test.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Additional evidence of infection is required to encourage acceptance and adherence (e.g., foreign-born healthcare workers who believe their positive TST is due to BCG). A positive IGRA might prompt greater acceptance of treatment for LTBI as compared with a positive TST alone.
*Another evidence of infection is needed to encourage acceptance and adherence (e.g., foreign-born healthcare workers who believe their positive TST is due to BCG). A positive IGRA may necessitate greater acceptance of treatment for LTBI as compared with a positive TST alone.
*The person has a low risk of both infection and progression from infection to TB disease. Requiring a positive result from the second test as evidence of infection increases the likelihood that the test reflects infection. An alternative is to assume, without additional testing, that the initial result is a false positive or that the risk for the disease does not warrant additional evaluation or treatment, regardless of test results.
*The individual has a low risk of both infection as well as progression from infection to TB disease. Requiring a positive result from the second test as evidence of infection increases the probability that the test reflects infection. An alternative is to suppose, without additional testing, that the initial result is a false positive or that the risk for the disease does not need additional evaluation or treatment, regardless of test results.
|-
|-
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" |<SMALL>Table adapted from CDC<ref name="CDC TST">{{cite web|url= http://www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm|title= CDC Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection }}</ref></SMALL>
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" |<SMALL>Table adapted from CDC<ref name="CDC TST">{{cite web|url= http://www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm|title= CDC Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection }}</ref></SMALL>
|}
|}


*In addition, repeating an IGRA or performing a TST might be useful when the initial IGRA result is indeterminate, borderline, or invalid and a reason for testing persists.
*Moreover, repeating an [[Interferon-γ release assays|IGRA]] or doing a [[TST]] may be of value when the initial [[Interferon-γ release assays|IGRA]] result is indeterminate, borderline, or invalid and a reason for testing persists.
*Multiple negative results from any combination of these tests cannot exclude M. tuberculosis infection. Steps should be taken to minimize unnecessary and misleading testing of persons at low risk.
*Several negative results from any combination of these tests do not exclude [[Mycobacterium tuberculosis|M. tuberculosis]] infection. We should take some steps to minimize unnecessary and misleading testing of individuals at low risk.
*Selection of the most suitable test or combination of tests for detection of M. tuberculosis infection should be based on the reasons and the context for testing, test availability, and overall cost of testing.
*Choosing the best [[test]] or combination of tests for detection of [[Mycobacterium tuberculosis|M. tuberculosis]] [[infection]] should be made according to the causes and the context for testing, test availability, and overall cost of testing.


==References==
==References==

Latest revision as of 08:51, 26 March 2021

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberculosis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberculosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberculosis laboratory findings

CDC on Tuberculosis laboratory findings

Tuberculosis laboratory findings in the news

Blogs on Tuberculosis laboratory findings

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Tuberculosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Alejandro Lemor, M.D. [3]

Overview

Routine laboratory exams are usually normal. The presence of acid-fast-bacilli (AFB) on a sputum smear or another specimen usually indicates TB disease and a positive culture for M. tuberculosis confirms the diagnosis. Other examples of laboratory tests are urinalysis, peritoneal fluid, or CSF analysis and Interferon-Gamma release assays (IGRA).

Laboratory Findings

Routine laboratory tests are usually normal. In some patients, the subsequent abnormalities could also be found:

Acid-Fast Bacilli

Acid-fast-bacilli in sputum smear

Presence of acid-fast-bacilli (AFB) on sputum smear or on another specimen usually indicates TB disease. Although acid-fast microscopy is easy and quick, it does not confirm a diagnosis of Tuberculosis as some acid-fast-bacilli are not M. tuberculosis. Consequently, a culture is done on all initial samples for confirmation of the diagnosis.

Sputum smears and cultures should be performed to detect acid-fast bacilli if the patient is producing sputum. The best method for this is fluorescence microscopy (auramine-rhodamine staining), which is more sensitive than conventional Ziehl-Neelsen staining.[1]

In case of inability of sufficient sputum production, specimens can be obtained by inducing sputum, gastric washings, a laryngeal swab, bronchoscopy with bronchoalveolar lavage, or fine-needle aspiration of a collection. A comparative study reported that inducing three sputum samples is more sensitive than three gastric washings.[2]

Other mycobacteria are also acid-fast. If the smear is positive, PCR or gene probe testing can differentiate M. tuberculosis from other mycobacteria. Even if sputum smear is negative, tuberculosis cannot be excluded without obtaining negative cultures.

Culture

A positive culture for M. tuberculosis confirms the diagnosis of TB disease. Culture examinations are crucial and should be done on all specimens, regardless of AFB smear results. Laboratories are necessary to report positive results on smears and cultures within 24 hours by telephone or fax to the primary health care provider and to the state or local TB control program, as needed by law.

Many types of cultures are available for M. tuberculosis, including Löwenstein-Jensen (LJ), Kirchner, or Middlebrook media. [3]. Culture of Mycobacteria often takes 4--8 weeks to grow and can help distinguish from several types of mycobacteria. Other kinds of culture are available, this include automated systems in which the mycobacteria grow at a faster rate. MB/BacT, BACTEC 9000, as well as the Mycobacterial Growth Indicator Tube (MGIT). The microscopic-observation drug-susceptibility (MODS) culture is considered a faster and more accurate method [4][5].

Culture: Distinctive clusters of colorless Mycobacterium tuberculosis
Löwenstein-Jensen media with Mycobacterium tuberculosis

A sample of pleural exudate should be analyzed by cytopathology or at a cell count lab. Samples are often lymphocyte predominant, and cytopathology is more accurate than cell count labs at detecting lymph. If there is more fluid present, then an AFB lab is more appropriate. Sometimes, a pleural exudate lab test find sterile pyuria (particularly in HIV positive patients), but overall this finding is fairly uncommon. Most extra-pulmonary TB is paucibacillary, hence the yield of tests is very low, and a negative test result does not exclude tuberculosis infection.

Drug Resistance

For all patients, the initial M. tuberculosis isolate should be tested for drug resistance. It is necessary to identify drug resistance as early as possible to ensure effective treatment. Drug susceptibility testing has to be repeated for patients who do not respond adequately to treatment or who have positive culture results despite 3 months of therapy. Susceptibility results from laboratories have to be reported to the primary health care provider and the state or local TB control programs.

Fluid Analysis

Urinalysis

Interferon-Gamma Release Assays (IGRAs)

Interferon-Gamma Release Assays (IGRAs) are whole-blood tests that aids in diagnosing Mycobacterium tuberculosis infection, but they do not differentiate latent tuberculosis infection (LTBI) from tuberculosis disease. Two IGRAs tests that are approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S include the QuantiFERON®-TB Gold In-Tube test (QFT-GIT) and the T-SPOT®.TB test (T-Spot).

IGRAs measure a person’s immune reactivity to M. tuberculosis antigen. White blood cells from most individuals that have been infected with M. tuberculosis will produce interferon-gamma (IFN-g) when mixed with antigens (substances that can produce an immune response) derived from M. tuberculosis.

To do this test, fresh blood samples should be mixed with antigens and controls. The antigens, testing methods, and interpretation criteria for IGRAs are different.

Differences in Currently Available IGRAs
QuantiFERON T-SPOT
Initial Process Process whole blood in 16 hours Process peripheral blood mononuclear cells (PBMCs) within 8 hours, or if T-Cell Xtend® is used, within 30 hours
M. tuberculosis Antigen Single mixture of synthetic peptides representing ESAT-6, CFP-10 & TB7.7. Separate mixtures of synthetic peptides representing ESAT-6 & CFP-10
Measurement Interferon-γ concentration Number of IFN-g producing cells (spots)
Possible Results Positive, negative, indeterminate Positive, negative, indeterminate, borderline
Table adapted from CDC [6]
Advantages and Disadvantages of IGRAs
Advantages Disadvantages
  • It requires a single patient visit to perform the test.
  • The results can be available within 24 hours.
  • There are no boosted responses that are measured by subsequent tests.
  • A history of previous BCG (bacillus Calmette-Guérin) vaccination does not yield a false-positive IGRA test result.
  • The blood samples should be processed within 8-30 hours after collection while white blood cells are still viable.
  • Errors in collecting or transporting blood specimens or in performing and interpreting the assay may reduce the accuracy of IGRAs.
  • There is limited data on the use of IGRAs to predict who will progress to TB disease in the future.
  • There is also limited data on the use of IGRAs for:
  • Children younger than 5 years of age
  • Persons recently exposed to M. tuberculosis
  • Immunocompromised persons
  • Serial testing
  • It may be expensive
Table adapted from CDC Interferon-Gamma Release Assays[6]

CDC Recommendations on When to Use IGRA Tests Adapted from CDC Interferon-Gamma Release Assays[6]

  • IGRAs can also be used in stead of (but not in addition to) TST in all conditions in which CDC recommends TST as an aid in diagnosing M. tuberculosis infection, with preferences and particular considerations noted below.
  • Contact investigations, testing during pregnancy, in addition to screening of health care workers, and others undergoing serial evaluation for M. tuberculosis infection.
  • In spite of the indication of a preference, the use of the alternative test (FDA-approved IGRA or TST) are approved medical and public health practice.
  • We should be alert in interpretation when testing particular populations due to limited data on the use of IGRAs
  • Populations in which IGRAs are preferred for testing:
  • Individuals who received BCG (either as a vaccine or for cancer therapy)
  • Individuals from groups that historically have less chances of coming back for TST reading.
  • TST is better than IGRAs for children less than 5 years of age.
  • As with TST, IGRAs generally should not be used for testing individuals who have a low risk of infection and a low risk of tuberculosis disease.

Routine testing with TST and IGRA is not recommended, but results from both tests may be useful in the following conditions:

When the initial test is negative and: When the initial test is positive and:
  • The risk for infection, the risk for progression to active disease, and the risk for a bad outcome are high (e.g., HIV-infected individuals or children under 5 years of age who are exposed to an individual with infectious TB).
  • Presence of clinical suspicion for TB disease (e.g., signs, symptoms, and/or radiographic evidence suggestive of TB disease) and confirmation of M. tuberculosis infection is needed.
  • Getting a positive result from a second test as evidence of infection increases detection sensitivity of the test.
  • Another evidence of infection is needed to encourage acceptance and adherence (e.g., foreign-born healthcare workers who believe their positive TST is due to BCG). A positive IGRA may necessitate greater acceptance of treatment for LTBI as compared with a positive TST alone.
  • The individual has a low risk of both infection as well as progression from infection to TB disease. Requiring a positive result from the second test as evidence of infection increases the probability that the test reflects infection. An alternative is to suppose, without additional testing, that the initial result is a false positive or that the risk for the disease does not need additional evaluation or treatment, regardless of test results.
Table adapted from CDC[6]
  • Moreover, repeating an IGRA or doing a TST may be of value when the initial IGRA result is indeterminate, borderline, or invalid and a reason for testing persists.
  • Several negative results from any combination of these tests do not exclude M. tuberculosis infection. We should take some steps to minimize unnecessary and misleading testing of individuals at low risk.
  • Choosing the best test or combination of tests for detection of M. tuberculosis infection should be made according to the causes and the context for testing, test availability, and overall cost of testing.

References

  1. Steingart K, Henry M, Ng V; et al. (2006). "Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review". Lancet Infect Dis. 6 (9): 570&ndash, 81. doi:10.1016/S1473-3099(06)70578-3.
  2. Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G (2007). "Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate". Clin Infect Dis. 44 (11): 1415–20. doi:10.1086/516782. PMID 17479935.
  3. Drobniewski F, Caws M, Gibson A, Young D (2003). "Modern laboratory diagnosis of tuberculosis". Lancet Infect Dis. 3 (3): 141–7. PMID 12614730.
  4. Moore D, Evans C, Gilman R, Caviedes L, Coronel J, Vivar A, Sanchez E, Piñedo Y, Saravia J, Salazar C, Oberhelman R, Hollm-Delgado M, LaChira D, Escombe A, Friedland J (2006). "Microscopic-observation drug-susceptibility assay for the diagnosis of TB". N Engl J Med. 355 (15): 1539–50. PMID 17035648.
  5. Minion, Jessica; Leung, Erika; Menzies, Dick; Pai, Madhukar (2010). "Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis". The Lancet Infectious Diseases. 10 (10): 688–698. doi:10.1016/S1473-3099(10)70165-1. ISSN 1473-3099.
  6. 6.0 6.1 6.2 6.3 "CDC Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection".

Template:WH Template:WS